arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

BridgeBio Pharma, Inc.

BBIO
$69.18 ▲ +2.63 (+3.95%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
35 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
52
Health
Fair
Neutral
auto_awesome

Analytical Summary

BridgeBio Pharma, Inc. demonstrates solid fundamentals with strength in Return on Common Equity (%). Overall, the data suggests a moderately positive outlook with manageable risks.

Market Cap $13.5B
Dividend Yield
Revenue Growth 120.4%
Op. Margin -43.9%
ROIC -77.8%
FCF / Share $-0.37
Trailing P/E
Price / Book
FCF Yield
Debt / Equity -1.05
info Valuation on last close. End-of-day price, Sep 22, 2026.

35-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$243.68M
↑ +120.4%
Net Income Profit after all expenses
$-155.89M
↑ +15.2%
Operating Margin Operating profit as % of sales
-43.9%
↑ +19.3% 2th
FCF / Share Free cash flow per share
$-0.37
↑ +63.9%
Long-Term Debt Long-term obligations
$2.65B
— 0.0%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
2
Returns
94
Financial Health
64
Cash Quality
45

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 10 years · 35 quarters